NASDAQ:RDNT - RadNet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.56 +0.08 (+0.59 %)
(As of 11/16/2018 11:24 AM ET)
Previous Close$13.48
Today's Range$13.48 - $13.79
52-Week Range$9.50 - $16.54
Volume3,356 shs
Average Volume249,109 shs
Market Capitalization$647.97 million
P/E Ratio46.55
Dividend YieldN/A
Beta0.36
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
Previous Symbol
CUSIPN/A
Phone310-478-7808

Debt

Debt-to-Equity Ratio4.56
Current Ratio1.12
Quick Ratio1.06

Price-To-Earnings

Trailing P/E Ratio46.55
Forward P/E Ratio39.88
P/E Growth4.95

Sales & Book Value

Annual Sales$922.19 million
Price / Sales0.72
Cash Flow$1.8008 per share
Price / Cash7.53
Book Value$2.48 per share
Price / Book5.47

Profitability

EPS (Most Recent Fiscal Year)$0.29
Net Income$50,000.00
Net Margins-0.44%
Return on Equity14.62%
Return on Assets1.75%

Miscellaneous

Employees7,440
Outstanding Shares48,870,000
Market Cap$647.97 million
OptionableOptionable

RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) posted its quarterly earnings results on Friday, November, 9th. The medical research company reported $0.10 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.15 by $0.05. The medical research company earned $242.10 million during the quarter, compared to analyst estimates of $240.07 million. RadNet had a positive return on equity of 14.62% and a negative net margin of 0.44%. The company's revenue was up 6.4% compared to the same quarter last year. During the same period last year, the company posted $0.12 earnings per share. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for RadNet.

What guidance has RadNet issued on next quarter's earnings?

RadNet updated its FY 2018 earnings guidance on Friday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $945-970 million, compared to the consensus revenue estimate of $968.47 million.

What price target have analysts set for RDNT?

3 brokerages have issued 1 year price targets for RadNet's shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate RadNet's stock price to reach $14.6667 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for RadNet.

Has RadNet been receiving favorable news coverage?

Media headlines about RDNT stock have trended positive this week, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. RadNet earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of RadNet's key competitors?

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Mr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 72)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 47)
  • Mr. Jeffrey L. Linden, Exec. VP & Gen. Counsel (Age 75)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 62)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 57)

Who are RadNet's major shareholders?

RadNet's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.40%), Renaissance Technologies LLC (4.51%), FMR LLC (4.36%), Dimensional Fund Advisors LP (3.25%), Robotti Robert (1.67%) and AQR Capital Management LLC (1.66%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Beck Mack & Oliver LLC, Acadian Asset Management LLC, Royce & Associates LP, ClariVest Asset Management LLC, AQR Capital Management LLC, Credit Suisse AG and EAM Global Investors LLC. Company insiders that have sold RadNet company stock in the last year include Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Cheyne Capital Management UK LLP, Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A., Matarin Capital Management LLC, Alliancebernstein L.P. and Man Group plc. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $13.57.

How big of a company is RadNet?

RadNet has a market capitalization of $647.97 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,440 workers across the globe.

What is RadNet's official website?

The official website for RadNet is http://www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVENUE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Featured Article: No Load Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel